Smartlab Europe

Press Releases

FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer), have entered into a worldwide agreement. The agreement enables drug...

XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development

XOMA Corporation announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in participants...

Recipharm and Medspray establish joint venture to exploit novel softmist technology for pharmaceutical applications

Recipharm AB , a leading contract development and manufacturing organisation (CDMO) and Medspray BV, a manufacturer of high tech spray nozzles, announce that they have agreed to establish a joint venture known as Resyca BV to develop and exploit...

Contract for innovative delivery system for COVID-19 vaccine

Croda International Plc , the speciality chemical company that uses smart science to create high performance ingredients and technologies that improve lives, announces that it has recently entered into an agreement with Pfizer Inc. to supply novel excipients used...

Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

Mallinckrodt plc, a global biopharmaceutical company, announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® (nitric oxide) gas, for inhalation therapy in patients...

InSilicoTrials presents a suite of highly innovative products that could revolutionize the global pharmaceutical industry

The global drug discovery market is growing rapidly: it is expected that it will reach 71 billion dollars by 2025, while in 2016 it was worth just 35.2 billion (source Statista 2020). Today, developing a new drug takes about...

Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID™, Altimmune’s next-generation, single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »